Your browser doesn't support javascript.
loading
Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
Reifsnider, Odette S; Kansal, Anuraag R; Franke, Jennifer; Lee, Joseph; George, Jyothis T; Brueckmann, Martina; Kaspers, Stefan; Brand, Sarah B; Ustyugova, Anastasia; Linden, Stephan; Stargardter, Matthew; Hau, Nikco.
Afiliação
  • Reifsnider OS; Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA.
  • Kansal AR; Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA.
  • Franke J; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Lee J; Evidera, San Francisco, CA, USA.
  • George JT; Boehringer Ingelheim Ltd., Bracknell, Berkshire, UK.
  • Brueckmann M; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Kaspers S; Faculty of Medicine Mannheim at the University of Heidelberg, Mannheim, Germany.
  • Brand SB; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Ustyugova A; Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA.
  • Linden S; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Stargardter M; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Hau N; Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA.
ESC Heart Fail ; 7(6): 3910-3918, 2020 Dec.
Article em En | MEDLINE | ID: mdl-32909680

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article